Skip to main content

Table 1 Summary of ceftolozane and tazobactam steady-state plasma exposures in patients with HABP/VABP

From: Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial

Exposure measure Statistic Ceftolozane Tazobactam
CrCl ≥ 80 to < 150 mL/min CrCL ≥ 150 to < 180 mL/min CrCL ≥ 180 to < 210 mL/min CrCL ≥ 210 mL/min CrCl ≥ 80 to < 150 mL/min CrCL ≥ 150 to < 180 mL/min CrCL ≥ 180 to < 210 mL/min CrCL ≥ 210 mL/min
AUC0–8 (μg × h/mL) n 138 24 16 20 138 24 16 20
Geometric mean (geometric %CV) 371 (55.3) 276 (52.6) 248 (59.7) 201 (67.2) 61.9 (80.1) 42.1 (56.2) 42.0 (90.7) 34.8 (85.6)
Cmax (μg/mL) n 138 24 16 20 138 24 16 20
Geometric mean (geometric %CV) 103 (42.6) 88.6 (40.2) 78.0 (52.7) 65.3 (63.0) 25.8 (45.0) 21.0 (34.3) 19.6 (43.6) 18.6 (48.8)
  1. Among all participants from the intention-to-treat population who had pharmacokinetic data collected
  2. AUC0–8, area under the concentration–time curve from time 0 to 8 h after start of infusion; Cmax, maximum drug concentration; CrCl, creatinine clearance; CV, coefficient of variation; HABP/VABP, hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia